Key Highlights

● Alphatec shares fell 27.7% in after-hours trading on Thursday after the third-quarter report.

● Third-quarter Revenue of $221.2 million missed the $225.2 million consensus, though it rose 12.6%.

● A brokerage downgraded the stock to Market Perform with an $8 price target.

● CEO Patrick Miles bought 115,000 shares on Sept. 10 at an average of $8.81.

Alphatec Holdings (NASDAQ:ATEC) is set for a rough Friday after its third-quarter report disappointed investors. The spine surgery technology company's shares fell 27.7% in after-hours trading on Thursday, according to an after-hours movers table at 7:08 p.m. ET, and another source put the after-hours drop at 30.1%. No confirmed pre-market quote for Friday was found, so the size of the move at the open is not yet known.

The trigger, per one summary, was that the chief executive said third-quarter revenue fell short of the company's own expectations. On Friday, a brokerage downgraded the stock to Market Perform from Outperform with an $8 price target, according to market data. That target implies about 29.6% downside from its $11.37 reference price, which reflects Thursday's regular-session close rather than the after-hours level.

Another brokerage also cut its target to $12 from $14 while keeping a Buy rating, with a market headline tying the cut to concerns about the company's Biologics business. The full note was not available.

What the numbers showed

Alphatec reported third-quarter revenue of $221.2 million, below the consensus of $225.2 million, though still up 12.6% from a year earlier, according to market data. Earnings Per Share were $0.09, a penny short of the $0.10 estimate and up from $0.03 a year ago.

For context, in its second-quarter report in August the company posted revenue of $214 million, up 15%, adjusted EBITDA of $36 million and positive free cash flow, and guided 2026 revenue to about $882 million and adjusted EBITDA to about $140 million. It could not be confirmed whether the third-quarter release changed that full-year outlook, which investors will be checking closely. A growth slowdown from 15% to roughly 13% in a Business priced for steady share gains is the kind of change that can trigger a sharp re-rating.

The company, the index and what to watch

Carlsbad, California-based Alphatec designs and sells spinal implants, surgical instruments, navigation and imaging systems including EOS, and intraoperative nerve monitoring. Its strategy is to win share from larger rivals by offering a full procedural ecosystem to spine surgeons.

The stock trades on the Nasdaq and is part of the Nasdaq Composite. With a Market Value of about $1.76 billion before the drop, according to market data, it is a small-cap medical device name. Medical technology stocks are not part of today's AI-driven tech selloff, so this move is company-specific, though Nasdaq-100 futures were down 2.62% around 8:03 a.m. ET, according to market quotes.

Sentiment had been mixed going in. Market data counted 12 Buy, 2 Hold and 1 Sell ratings with a consensus target of $17 before Friday's changes. CEO Patrick Miles bought 115,000 shares on Sept. 10 at an average of $8.81, a signal of confidence that investors may revisit if the stock falls toward that level.

Key risks include slower surgeon adoption, pricing pressure in spine implants, weakness in biologics, and the company's ongoing net losses; analysts expect a full-year loss of $0.45 a share, according to market data. Watch for more analyst revisions after the open, any detail from management's call on the shortfall and the full-year outlook, and whether insiders step in again. Investors will also want to know whether the shortfall reflects timing, such as delayed surgeries or slower hiring of sales reps, or a more lasting loss of momentum, because the answer will shape how quickly the market is willing to give the company the benefit of the doubt again.